Led · Equity · Nov 2024

FastBooking operates a direct-booking platform for hoteliers, offering a booking engine for hotel websites, its own distribution sites (www.fastbooking.com and www.only-recommended-hotels.com), GDS/IDS connectivity and e-marketing tools. The company targets independent hoteliers and some hotel chains. It serves 3,500+ client hotels worldwide and has facilitated over 2 million hotel room nights through its platform this year. FastBooking has a strong presence across most European countries and is active in Asia and North America. Management intends to pursue growth driven by increasing direct bookings and further expansion by acquisition, building on its leadership position in the European hotel bookings market.

Participated · Series C · Oct 2024

BE WTR is a Swiss-founded company offering sustainable, premium on-site water solutions that deliver filtered, flavored water in stylish glass bottles as a circular alternative to single-use plastics. Its core product portfolio centers on water distribution, purification and circular bottling operations for residential, commercial and hospitality customers. The company recently launched in Singapore and is pursuing broader expansion across Asia. BE WTR plans to use new funding to enhance its market-leading product lineup and to invest in research and development. Management also intends to extend the company’s international footprint, including targeted openings in China and North America and further activity in Switzerland. The firm emphasizes innovation in sustainability and aims to set new benchmarks for water consumption and waste reduction.

Participated · Equity · Jan 2024

Oncodesign Services provides preclinical research services and has moved to expand its capabilities through acquisitions. The recent investment financed the purchase of Dutch company ZoBio, which specializes in preclinical research for small molecules. Management describes the deal as the first transformative acquisition since the creation of Oncodesign Services as it seeks to become a full-service preclinical research provider. The transaction increased the group's reported revenue to €44 million and its headcount to nearly 280 employees. About fifty of those employees are based in Leiden, the Netherlands.

Participated · Series C · Jul 2017

Complexa is a clinical-stage biopharmaceutical company based in Radnor, Pa., led by President and CEO Josh Tarnoff. The company is advancing CXA-10, an oral nitrated fatty acid (NFA) compound that upregulates Nrf2 and inhibits NF-κB to reduce inflammation and fibrosis. Complexa leverages a proprietary platform to develop endogenous NFAs to restore anti-inflammatory and tissue-repair pathways in diseases with high oxidative stress. Its lead program targets focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), with a Phase 2 trial of oral CXA-10 in FSGS expected to start in early 2018. The company completed a $62M Series C to fund clinical development of CXA-10 and to advance a second compound toward an IND for a yet-to-be-disclosed indication. Complexa is a clinical-stage, platform anti-inflammatory and fibrotic disease-focused biopharmaceutical company based in Pittsburgh, PA. Its proprietary technology centers on the synthesis and therapeutic application of endogenous nitro-fatty acids (NFAs) and related structure/function mediators. The company’s lead compound is CXA-10, being developed in two formulations: an intravenous formulation currently in Phase I for a form of acute kidney disease, and an oral formulation for a form of chronic kidney disease for which an IND will be filed later this year. Complexa is led by President and CEO Josh Tarnoff. The company will use proceeds from its recent financing to further advance clinical development of both CXA-10 formulations. No operating metrics were disclosed in the article. Complexa, founded in 2008 and based in Pittsburgh, develops nitrated unsaturated fatty acids to treat inflammatory and metabolic disorders. Its initial clinical focus is acute and chronic kidney disease, and its lead compound, CXA-10, is targeted at contrast imaging–induced nephropathy (CIN), a form of acute kidney injury. CIN can lead to extended hospitalization, dialysis, or death. The company also has several proprietary second‑generation drug candidates that are structurally distinct from CXA‑10 and are being developed to target significant inflammatory and metabolic conditions. These candidates are intended to facilitate future partnering opportunities. Financially, Complexa raised $200K in the reported financing, a follow‑on investment from Pittsburgh Life Sciences Greenhouse (PLSG). PLSG, managing member of the PLSG Accelerator Fund, has invested a total of $550,000 into the company.

Participated · Series B · Jun 2017

LogicBio Therapeutics focuses on disease-modifying gene therapies for orphan paediatric diseases by combining gene therapy and editing in a one-time treatment. The company was founded with core platform technologies discovered by Dr Adi Barzel (Tel Aviv University), Dr Leszek Lisowski (Children’s Medical Research Institute, Australia), and Professor Mark Kay (Stanford). Its first platform, GeneRide, uses homologous recombination to enable precise, site-specific transfer of therapeutic genetic material without promoters or nucleases. LogicBio also has access to a library of synthetic, non-pathogenic recombinant AAV vectors developed at Stanford to improve predictability of vector performance in clinical trials. The company has additional science teams working in Tel Aviv. LogicBio intends to use the funds to advance gene therapies targeting orphan paediatric disorders through clinical trials. The company has raised approximately $50M in financing to date. LogicBio Therapeutics develops recombinant adeno-associated virus (rAAV)-mediated gene targeting therapies aimed at inherited diseases, notably hemophilia; its work has been discussed alongside CRISPR gene-editing approaches. The company's LinkedIn lists programs targeting hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Founded in 2014 by Adi Barzel, LogicBio is led by CEO Leszek Lisowski and lists directors including OrbiMed Israel’s Erez Chimovitz and Stanford’s Mark Kay. The startup remains fairly stealth and does not appear to have a public website. According to a regulatory filing, LogicBio has brought in $4 million of a proposed $5.4 million early capital raise. Company descriptions emphasize a proprietary, non-pathogenic AAV vector intended to offer improved efficiency and safety and to be suitable for treating both children and adults.